key: cord-0796512-g8u6no6i
authors: Eales, O.; de Oliveira Martins, L.; Page, A.; Wang, H.; Bodinier, B.; Tang, D.; Haw, D.; Jonnerby, J.; Atchison, C.; Ashby, D.; Barclay, W.; Taylor, G.; Cooke, G.; Ward, H.; Darzi, A.; Riley, S.; Elliott, P.; Donnelly, C. A.; Chadeau-Hyam, M.
title: The new normal? Dynamics and scale of the SARS-CoV-2 variant Omicron epidemic in England
date: 2022-04-04
journal: nan
DOI: 10.1101/2022.03.29.22273042
sha: d2c19c02721568c3c82a2662b5ee2782aefce296
doc_id: 796512
cord_uid: g8u6no6i

The SARS-CoV-2 pandemic has been characterised by the regular emergence of genomic variants which have led to substantial changes in the epidemiology of the virus. With natural and vaccine-induced population immunity at high levels, evolutionary pressure favours variants better able to evade SARS-CoV-2 neutralising antibodies. The Omicron variant was first detected in late November 2021 and exhibited a high degree of immune evasion, leading to increased infection rates in many countries. However, estimates of the magnitude of the Omicron wave have relied mainly on routine testing data, which are prone to several biases. Here we infer the dynamics of the Omicron wave in England using PCR testing and genomic sequencing obtained by the REal-time Assessment of Community Transmission-1 (REACT-1) study, a series of cross-sectional surveys testing random samples of the population of England. We estimate an initial peak in national Omicron prevalence of 6.89% (5.34%, 10.61%) during January 2022, followed by a resurgence in SARS-CoV-2 infections in England during February-March 2022 as the more transmissible Omicron sub-lineage, BA.2 replaced BA.1 and BA.1.1. Assuming the emergence of further distinct genomic variants, intermittent epidemics of similar magnitude as the Omicron wave may become the 'new normal'.

variant. We further explore the diversity of Omicron sub-lineages in round 16 December), 17 (5 January -20 January) and 18 (8 February -1 March) and how they have contributed to the overall dynamics.

Within the REACT-1 samples we estimated Omicron prevalence of 0.11% (0.07%, 0.16%) by 7 December 2021 (Fig. 1A) , three weeks after the first confirmed Omicron case in England was sampled (16 November, linked to recent travel) [22] . At the same date Delta, which had been at a steady high prevalence for the preceding 3 months, was estimated to be approximately twelve-fold higher at 1.31% (1.17%, 1.47%). Though the Omicron variant was likely introduced to England by international travel from Southern Africa [22] , we find greater levels of similarity between REACT-1 sequences and sequences sampled in the USA, Germany and France (Sup Fig. 1 ) with inferred high rates of importation/exportation from/to these countries (Sup Fig. 2 ). This likely reflects greater rates of transmission between England and USA/Europe after Omicron was globally disseminated. The proportion of cases in England linked to Omicron rapidly increased, reaching 50% by 14 December We measured an average daily growth rate in the log-odds of Omicron infection of 0.21 (0.20, 0.23) during rounds 16 to 18 (23 November 2021 -1 March 2022). However, our results suggest that the growth advantage was not constant over time and ranged from 0.37 (0.28, 0.49) on the 3 December (first day Omicron detected in the REACT-1 study) declining steadily to 0.11 (0.03, 0.17) on 8 January (Fig. 1C ). This change in growth advantage over time could be explained by a shorter generation time for Omicron [15] estimated to be approximately 28% shorter than that of Delta [15] . The decline in growth rate may reflect the virus initially achieving higher average rates of transmission among younger and more socially active groups than in the population as a whole [23] . A similar decrease in growth advantage over time was detected when the Alpha variant emerged in England during late 2020 [3] .

Models fit to the nine regions of England (Sup Figs. [3] [4] [5] and to four broad age-groups (Sup Figs. [6] [7] [8] found similar growth advantages in all regions and age-groups. Trends in the proportion of cases that were Omicron showed a high degree of synchrony across regions, but there was some asynchronous behaviour between age-groups. We estimated a 50% proportion Omicron by 10 December (8 December, 14 December) 2021 for 18-34 year olds which was faster than for 5-17 year olds (50% proportion by 25 December (22 December, 29 December) 2021), though this may reflect differences in the prevalence of Delta before Omicron emerged (higher prevalence in 5-17 year olds) (Sup Fig. 6 ).

As the prevalence of Omicron increased, the prevalence of Delta dropped rapidly to below 0.1% on 3 January 2022 (30 December 2021, 6 January 2022) (Fig.1A) with similar decreases observed in all regions (Sup Fig. 3 ) and age-groups (Sup Fig. 6 ). For Delta, we estimated that the time-varying reproduction number ( ) halved in the three weeks from 9 December to 30 December 2021 with values of 1.00 (0.91, 1.10) and 0.50 (0.38, 0.66) respectively ( Fig. 2A) . The rapid increase in Omicron infections leading to a depletion of the population susceptible to Delta may at least partially explain this reduction in . The contribution to that drop of changes in behaviours [24] and public health measures aimed at reducing transmission [25] remains uncertain.

The epidemic curve for Omicron swab-positivity had a high initial peak followed by a plateau and possible resurgence (Fig.1A) . The national prevalence of Omicron increased rapidly reaching a maximum value of 6.89% (5.34%, 10.61%), on 30 December 2021 (21 December 2021, 31 January 2022) (Sup Fig. 9 , Sup Tab. 1). During January prevalence decreased to 4.18% (4.00%, 4.37%) on 12 January where it plateaued with the beginnings of a resurgence detected in late-January 2022 (Fig.  1A) . By early-March 2022 prevalence was approximately constant at 2.60% (2.20%, 3.04%) on 1 March (the last official day of round 18 of the study). Trends in the 2-week average instantaneous reproduction number, ( Fig.2A) , showed that on 17 December 2022 (2 weeks after first Omicron detected) was well above one with a value of 1.99 (1.75, 2.29) despite high levels of vaccine coverage (1 dose 89.8% of those 12 years or older, 2 doses 82.1%, 3 doses 56.9%) [26] . Into early January 2022 rapidly decreased with the central estimate falling below one on 2 January 2022 before rising to above one in late January (21 January to 1 February). Through February 2022 was below one, but at the end of round 18 was no longer securely below one with an value of 1.00 (0.88, 1.12) on 1 March 2022, and a probability of >1 of 0.50.

During December 2021 Omicron's prevalence rapidly increased in all regions of England (Fig. 2B ) though there was heterogeneity in the timing and magnitude of the peak (Sup Fig. 9 , Sup Tab. 1). The maximum prevalence reached was highest in the North East at 7.37% (6.42%, 9.79%) and lowest in the East of England at 3.98% (3.38%, 5.80%). Maximum prevalence was reached fastest in London, peaking at 6.45% (5.15%, 10.27%) on 29 December 2021 (25 December 2021, 28 January 2022). In contrast, prevalence reached a maximum of 4.12% (3.21%, 6.36%) in the South West on 3 February (11 January, after 1 March) 2022, approximately 5 weeks later than in London. The rapid rise in prevalence in London could not be explained by a higher regional value of with estimates in December being highly comparable between all regions (Sup Fig. 10 ) and may therefore be related to an earlier introduction of Omicron in London. Trends over time in regional estimates were comparable across regions and followed a similar pattern as the national estimates. On 1 March central estimates of were above one in 4 regions: North East, East of England, London and West Midlands.

Trends over time in age-group specific also showed a high degree of synchrony (Sup Fig. 11 ).

However, in those aged 5-17 years old was found to be higher in January 2022 relative to other age-groups (although lower in February) leading to a longer initial period of uninterrupted growth whilst for other age-groups dropped below one in early-January 2022. Prevalence in 5-17 year olds ( Fig. 2C ) peaked on 28 January (21 January, 1 February) 2022, reaching a maximum prevalence of 10.74% (8.52%, 14.74%). This was almost 50% higher than the next highest age-group (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) year olds), which had a maximum prevalence of 7.65% (6.08%, 12.35%) approximately 4 weeks earlier on 1 January 2022 (27 December 2021, 5 January 2022) (Sup Fig. 9 , Sup Tab. 1). The prevalence was lowest in those aged 55 and over with a maximum prevalence of 3.67% (3.25%, 4.88%) reached on 7 January (1 January, after 1 March) 2022. However, there was indication that prevalence in this group was increasing at the end of the study, with an estimate of 1.14 (0.97, 1.33) on 1 March, a greater estimate than in the other age-groups.

The proportion of the Omicron sub-lineage BA.1 decreased over rounds 16, 17 and 18 of REACT-1 (Sup Tab. 2) with the proportion of BA.2 increasing over the same period, and the proportion of BA.1.1 increasing up to 8 February (7 February, 9 February) 2022 (Fig. 3A) ; as we do not estimate a higher growth advantage in these two regions the greater proportion of BA.2 suggests earlier introductions there, in agreement with the higher rates of international travel from these regions [31] . Phylogeographic analysis further supported this with London being highly represented in estimates for the regions of many ancestral nodes within Omicron's phylogenetic tree (Sup Fig. 19 ). However, during periods in which the Omicron sub-lineages were well-sampled there was little geographic structure present in Omicron's phylogeny. This is potentially due to the rapid time-frame by which each Omicron sub-lineage in turn was disseminated across the country following their introduction in London. We estimated higher symmetrical region-to-region migration rates from London to other regions over all rounds and for each Omicron sub-lineage (Sup Tab. 5); they were most consistently high for London to South East and London to North West.

The estimated proportion of BA. 

Our study has limitations. The sampling is performed over discrete rounds with periods of no data, for which trends have to be inferred. One such period was late December 2021, a key period of growth in the proportion of SARS-CoV-2 infections caused by the Omicron variant, leading to wide credible intervals for the dynamics of the pandemic over this period. Sequencing is unlikely to be successful on samples with a low viral load and so was only performed on samples with an N-gene cycle threshold (Ct) value (a proxy for viral load) less than 34. However, it is unknown if there are intrinsic differences in the Ct values by lineage which could bias estimated proportions. Further, differences in Ct values due to differences in growth rate [32] could also lead to more transmissible variants being detected more favourably.

Finally, our study estimates the daily prevalence, the proportion of the population testing positive, and not the incidence. This can lead to estimates of being overly smoothed due to swab-positivity remaining over several days [33, 34] , and trends of over time may be lagged by a period depending on the duration for which individuals test positive. It is also worth noting that our estimates of are based on specific estimates of the generation time distribution; studies using different generation time distributions will return different estimates of [35] . Additionally our region-and age-group-specific estimates assume that all infections in a particular subgroup result from contact/mixing among members of that subgroup and so, though highly informative, must be interpreted cautiously.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 4, 2022. ; https://doi.org/10.1101/2022.03.29.22273042 doi: medRxiv preprint

As the cumulative incidence and vaccination coverage continue to increase, the SARS-CoV-2 virus will find itself competing against a diverse and complex immunity landscape within the human population. Accordingly, the evolutionary dynamics of the virus will be dominated by immune evasion. This has already been observed with the emergence of the Omicron variant and its sub-lineages, the consequence of which was an initial wave of infection peaking at a prevalence of 6.89% in England, the highest recorded at any time hitherto in the REACT-1 study. These infection rates occurred against a background of high levels of vaccine coverage and past infections, further fuelled by the emergence of the more transmissible Omicron sub-lineage BA.2. Given the regular emergence of VOCs during the first two years of the COVID-19 pandemic there is little reason to believe this trend will not continue. Indeed, other respiratory infections such as Influenza observe annual epidemics due to the emergence of new strains better able to navigate the immune landscape [36,37]. If we see a similar trend for SARS-CoV-2 then intermittent waves of infection of a similar magnitude to Omicron are within the bounds of possibility. Continued surveillance, booster vaccinations and, potentially, updates of the vaccines will be crucial in minimising the harmful effects of this new public health paradigm. Greater vaccine equity worldwide can help reduce the rate at which these harmful variants emerge [38] .

The methodology of REACT-1 has been described in detail elsewhere [39] . In short, each round a random subset of the population in England is selected at the lower tier local authority (LTLA) level (N=315) and invited to participate in the study. Those who agree to participate provide a self-administered (parent/guardian administered for those aged 5-12 years old) throat and nose swab which undergoes rt-PCR testing for the SARS-CoV-2 virus. Individuals are classified as positive if their test has an N-gene Ct value less than 37 or if both the N-and E-gene are detected. Rim weighting [40] is used to weight individual test results by age, sex, deciles of the Index of Multiple Deprivation, LTLA counts, and ethnic group. Analysis was performed using rounds 14 to 18 of the study running from 9 September 2021 to 1 March 2022. During rounds 15 to 18 of the study all swab tests were sent to the lab via the post, whereas in round 14 of the study approximately 50% of tests were collected via courier. No difference in samples were observed for the two different collection methods [41] .

All swab tests with an N-gene Ct value less than 34 and sufficient volume underwent genomic sequencing. Extracted RNA was amplified using the ARTIC protocol [42] with sequence libraries provided by CoronaHiT [43] . Sequencing was performed on the Illumina NextSeq 500 platform. Analysis of the raw sequencing was done using the bioinformatics pipeline [44] before being uploaded to CLIMB [45] . Lineage designation was then performed using PangoLEARN [46] (database version 2022-02-28), a machine-learning based algorithm for lineage designation which uses the PANGO nomenclature [5] . Sequences could not be obtained for some samples of low overall quality. Further, samples for which at least 50% of bases were not covered were excluded from the analysis.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 4, 2022. ; https://doi.org/10.1101/2022.03.29.22273042 doi: medRxiv preprint

A mixed-effects Bayesian P-spline model was used to estimate the prevalence of both Omicron and Delta SARS-CoV-2 infections over time. The basic Bayesian P-spline model has been described in detail [47] . In short, the entire time series is split into equally sized knots (approximately 5 days apart) with 3 further knots defined at both the beginning and end of the time series (to prevent edge effects). A system of 4th order basis-splines (b-splines) is defined over all knots. The P-spline for a single lineage's prevalence is then defined as a linear combination of these basis splines:

.

Here is the logit link function, is the prevalence on day , are the b-spline coefficients, and . This assumes that changes in the growth rate happen η, ρ ~ (0. 001, 0. 001) simultaneously for both Omicron and Delta, which effectively assumes a constant growth rate advantage, unless there is significant evidence to the contrary.

The sum total of Omicron and Delta's modelled prevalence is fitted to the daily weighted number of tests and positive tests assuming a binomial likelihood. Simultaneously the proportion of the total prevalence attributed to Omicron is fitted to the daily number of Omicron lineages vs total number of samples with a lineage determined, again assuming a binomial likelihood. The model is fit to rounds 14 to 18 of the REACT-1 data using a No-U-Turns sampler [48] implemented in STAN [49] . Models are also fit to the data subset by region of England, and subset by age quartile. An analogous model is fit to rounds 17 and 18 instead comparing BA.2 and non-BA.2 Omicron lineages under the assumption that total prevalence was caused only by Omicron lineages (>99% Omicron in both rounds).

Estimates of the instantaneous growth rate of Omicron, Delta and their difference were estimated over time from the modelled prevalence time-series. The rolling two-week average reproduction number for both Omicron and Delta was also estimated from the modelled prevalence using methodology that has previously been described [47] . The model assumed a gamma-distributed generation time with rate parameter = 0.27, and shape parameter = 0.89, for Omicron or Omicron sub-lineages (BA.2, non-BA.2 Omicron lineages) and rate parameter = 0.48 and shape parameter = 2.20 for Delta [15] .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 4, 2022. ; https://doi.org/10.1101/2022.03.29.22273042 doi: medRxiv preprint

The daily growth rate in the log-odds of Omicron infection relative to Delta infection, assuming a constant growth rate for the whole period, was estimated using a Bayesian logistic regression model fit to a binary outcome variable (Omicron or Delta) over time. The daily growth rate in the log-odds of BA.2 and BA.1.1 relative to BA.1 over rounds 17 and 18, assuming constant growth rates, was estimated using a Bayesian multinomial logistic regression model fit to the categorical outcome variable (BA.1, BA.1.1 or BA.2) with BA.1 set as the reference category. The difference in these two growth rates was used to estimate the daily growth rate in the log-odds of BA.2 relative to BA.1.1.

Phylogeographic analysis was performed on lineages that were designated as Omicron (BA.1, BA.1.1, BA.2). A maximum likelihood phylogenetic tree assuming a HKY model was fitted to the sequences using IQTree [50] . A relaxed molecular clock model, assuming a mean evolutionary rate of 0.0008 substitutions/site/year, was fit to the tree using TreeTime [51] to give a time-resolved phylogenetic tree. A further mugenic model again implemented in TreeTime [51] was fit to the time-resolved phylogeny treating the region of England (N=9) where each sample was obtained as a discrete state. From this model we estimated the mean pairwise migration rate of Omicron between all regions of England. We excluded sequences without complete date information since they do not contribute to the estimation of divergence times. Sequences with an excess of gaps cannot be placed in the phylogeny correctly, and so we excluded sequences with less than 75% of bases covered. Note that this is a more stringent threshold than was used earlier for the task of lineage classification which can be performed for sequences with fewer bases covered. We further excluded one sequence which deviated too much from a preliminary strict clock (more than five times the interquartile range from the clock regression).

Omicron sequences with at least 75% of bases covered were compared to all sequences deposited in GISAID after the 2nd Dec 2021, with the 500 closest neighbours extracted using uvaiann [52] . The similarity measure is based on the number of single nucleotide polymorphism (SNP) matches, number of partial matches, and number of valid comparisons so that we prefer more resolved sequences. Matches to GISAID samples from the REACT-1 study were excluded afterwards. We then compared the number of samples that match (no different SNPs) a REACT-1 sequence by the country where they were collected. We additionally investigated the number of samples that were at specific SNP distance (1,2,3 and 4 SNP mismatches) from REACT-1 sequences again by the country where they were collected. The reported number of SNP mismatches considers partially ambiguous DNA codes: DNA bases which cannot be unambiguously inferred by the assembler may be reported as e.g. 'M' to indicate that the base may be an adenine (A) or a cytosine (C) [53] . Such a state is compatible and thus considered a match to another sequence which has for instance an 'A' in the same genomic location.

In order to estimate potential Omicron importations into and exportations from England based on the REACT-1 samples, we used the set of closest neighbours described above, restricting to global sequences sampled within one week of REACT-1 samples with at most one SNP distance. We furthermore removed global GISAID matches from the UK (i.e. sequences deposited in GISAID from the UK), and for each REACT-1 sequence we kept only the global match with the highest number of valid pair comparisons (locations where neither sequence is a gap or have low coverage). After removing duplicate hits, since the same global reference can be the best match for more than one . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 4, 2022. ; https://doi.org/10.1101/2022.03.29.22273042 doi: medRxiv preprint REACT-1 sequence, we inferred a potential importation if the sampling date of the global sequence is earlier than its matching REACT-1 sample, and as a potential exportation if the REACT-1 sample is earlier (but still within one week). Global sequences which matched both an earlier and a later REACT-1 sample were removed (since they could be inferred as a source or destination of the migration). In total we have 335 imported samples and 310 exported ones. The date of the importation/exportation was taken as the date of the second sample for each pair. The actual import/export dates may be earlier due to an importation lag [54] .

The Wilson method [55] which is prefered for low numbers of positives [56] was used to calculate the 95% confidence intervals for all lineage proportions.

The proportion of individuals reporting any symptoms, and the proportion reporting the most predictive COVID-19 symptoms (loss or change of sense of smell or taste, fever, new persistent cough) [57] in the last month was estimated in round 16 for those infected with Omicron and Delta, and in rounds 17-18 for those infected with BA.1, BA.1.1 and BA.2. The combination of lineages and rounds chosen was done to avoid introducing biases due to changing rates of symptoms over time, and to ensure a large enough sample of each lineage for calculations to be meaningful. P-values for differences in the proportion reporting symptoms between lineages was estimated using logistic regression models with symptom status (any symptom vs no symptoms and separately most predictive COVID-19 symptoms vs not reporting the most predictive COVID-19 symptoms) as the outcome variable. The sensitivity of any result that was significant (P-value <0.05) was assessed using multivariable logistic regression models including round of the study and N-gene Ct value as additional covariates.

We obtained research ethics approval from the South Central-Berkshire B Research Ethics Committee (IRAS ID: 283787). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 4, 2022. ;

Radiation Threats and Hazards, and has no conflict of interest to disclose. Prof M Chadeau-Hyam holds shares in the O-SMOSE company and has no conflict of interest to disclose. Consulting activities conducted by the company are independent of the present work. All other authors have no conflict of interest to disclose.

The study was funded by the Department of Health and Social Care in England. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of this manuscript. We thank GISAID for providing global SARS-CoV-2 sequences and gratefully acknowledge all authors (see supplementary materials 'gisaid_acknowledgements.xlsx' ) from the originating laboratories responsible for obtaining the specimens and the submitting laboratories where genetic sequence data were generated and shared via the GISAID Initiative.

Access to REACT-1 individual-level data is restricted to protect participants' anonymity.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 4, 2022. Summary statistics, descriptive tables, and code from the current REACT-1 study are available at https://github.com/mrc-ide/reactidd (doi 10.5281/zenodo.6242826). REACT-1 study materials are available for each round at https://www.imperial.ac.uk/medicine/research-and-impact/groups/react-study/react-1-study-materi als/ Sequence read data are available without restriction from the European Nucleotide Archive at https://www.ebi.ac.uk/ena/browser/view/PRJEB37886, and consensus genome sequences are available from the Global initiative on sharing all influenza data (GISAID). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 4, 2022. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 4, 2022. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 4, 2022. ; https://doi.org/10.1101/2022.03.29.22273042 doi: medRxiv preprint Supplementary Figure 3 : Omicron vs Delta prevalence by region Modelled prevalence of SARS-CoV-2 variants Omicron (pink) and Delta (green), and total prevalence (grey) in each region of England estimated using mixed-effects Bayesian P-spline models. Estimates of prevalence are shown with a central estimate (solid line) and 95% (shaded region) credible intervals. Daily weighted estimates of prevalence (points) are shown with 95% credible intervals (error bars).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 4, 2022. ; https://doi.org/10.1101/2022.03.29.22273042 doi: medRxiv preprint Supplementary Figure 5 : Omicron vs Delta growth rate by region Daily growth rate of Omicron (purple), Delta (orange) and their additive difference (green) estimated from mixed-effects Bayesian P-spline models fitted to each region of England. Estimates are shown with a central estimate (solid line) and 95% credible intervals (shaded region). Estimates for each lineage are only displayed for the period over which the lineage was detected in REACT-1 samples.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 4, 2022. ; https://doi.org/10.1101/2022.03.29.22273042 doi: medRxiv preprint Supplementary Figure 6 : Omicron vs Delta prevalence by age-group Modelled prevalence of SARS-CoV-2 variants Omicron (pink) and Delta (green), and total prevalence (grey) for each age-group in England estimated using mixed-effects Bayesian P-spline models. Estimates of prevalence are shown with a central estimate (solid line) and 95% (shaded region) credible intervals. Daily weighted estimates of prevalence (points) are shown with 95% credible intervals (error bars).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 4, 2022. ; https://doi.org/10.1101/2022.03.29.22273042 doi: medRxiv preprint

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

Detection of a SARS-CoV-2 variant of concern in South Africa

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa

SARS-CoV-2 Variant of Concern

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study

Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario

Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

The Spread of SARS-CoV-2 Variant Omicron with a Doubling Time of 2.0-3.3 Days Can Be Explained by Immune Evasion

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. medRxiv

Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa

Estimation of the test to test distribution as a proxy for generation interval distribution for the Omicron variant in England

Bounding the levels of transmissibility & immune evasion of the Omicron variant in South Africa

Enhancing response to Omicron SARS-CoV-2 variant: Technical brief and priority actions for Member States. World Health Organization

Epidemic Surveillance of Covid-19: Considering Uncertainty and Under-Ascertainment

Lateral flow test shortage hits two in five Britons. YouGov

Tracking COVID-19 infections: time for change

Resurgence of SARS-CoV-2: Detection by community viral surveillance

UKHSA Contact Tracing Data Team, UKHSA Environmental Monitoring for Health Protection Team, Contributions from the Variant Technical Group Members. SARS-CoV-2 variants of concern and variants under investigation in England -Technical briefing

UKHSA Contact Tracing Data Team, UKHSA Environmental Monitoring for Health Protection Team, Contributions from the Variant Technical Group Members. SARS-CoV-2 variants of concern and variants under investigation in England -Technical briefing 32

Social contacts in the UK from the CoMix social contact survey Report for survey week 101 -Final report. CMMID COVID-19 seasonal influenza A (H3N2) viruses

Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination

REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol

Weighting survey results

SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys

nCoV-2019 sequencing protocol v3 (LoCost)

CoronaHiT: high-throughput sequencing of SARS-CoV-2 genomes

A Nextflow pipeline for running the ARTIC network's field bioinformatics tools. Github

CLIMB (the Cloud Infrastructure for Microbial Bioinformatics): an online resource for the medical microbiology community

Phylogenetic Assignment of Named Global Outbreak LINeages (PANGOLIN). Github

Appropriately smoothing prevalence data to inform estimates of growth rate and reproduction number

The No-U-Turn Sampler: Adaptively Setting Path Lengths in Hamiltonian Monte Carlo. arXiv

RStan: the R interface to Stan

IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies

TreeTime: Maximum-likelihood phylodynamic analysis

Reference-based alignment and sequence database search. Github

An extended IUPAC nomenclature code for polymorphic nucleic acids

Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK

Probable Inference, the Law of Succession, and Statistical Inference

Interval Estimation for a Binomial Proportion

Predictive symptoms for COVID-19 in the community: REACT-1 study of over 1 million people

Supplementary Figure 7: Omicron vs Delta proportion by age-group Modelled proportions of lineages identified as Omicron for each age-group in England estimated using mixed-effects Bayesian P-spline models. Estimates are shown with a central estimate (solid line) and 95% credible intervals (shaded region). Daily estimates of the proportion of lineages Omicron (points) are shown with 95% credible intervals

 Figure 9 : Maximum prevalence and date of maximum prevalence The maximum prevalence of Omicron reached and the date at which it was reached inferred from the mixed-effects Bayesian P-spline model fitted to all data, and for the models fit to subsets of data by region and age-group. Estimates are shown for the median value (points) with 95% credible intervals (error-bars).